injectable microfoam for sclerotcraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.
|
0. 21. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of oxygen.
0. 29. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of oxygen in a hermetic container.
0. 25. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of a mixture of oxygen and carbon dioxide.
0. 33. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of a mixture of oxygen and carbon dioxide in a hermetic container.
0. 1. Prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance.
0. 2. injectable microfoam for therapeutic uses, according to
0. 3. injectable microfoam for therapeutic uses, according to
0. 4. injectable microfoam for therapeutic uses, according to
0. 5. injectable microfoam for therapeutic uses, according to
0. 6. injectable microfoam for therapeutic uses, according to
0. 7. injectable microfoam for therapeutic uses, according to
0. 8. injectable microfoam for therapeutic uses, according to
0. 9. A method for phlebologic treatment comprising injecting the microfoam of
0. 10. A method for phlebologic treatment comprising injecting the microfoam of
0. 11. A method for phlebologic treatment comprising injecting the microfoam of
0. 12. A method for treatment of esophageal varices comprising injecting the microfoam of
0. 13. A method for treatment of esophageal varices comprising injecting the microfoam of
0. 14. A method for treatment of esophageal varices comprising injecting the microfoam of
0. 15. A method for proctologic treatment comprising injecting the microfoam of
0. 16. A method for proctologic treatment comprising injecting the microfoam of
0. 17. A method for proctologic treatment comprising injecting the microfoam of
0. 18. A method for angiologic treatment comprising injecting the microfoam of
0. 19. A method for angiologic treatment comprising injecting the microfoam of
0. 20. A method for angiologic treatment comprising injecting the microfoam of
0. 22. The injectable microfoam of
0. 23. The injectable microfoam of
0. 24. The injectable microfoam of
0. 26. The injectable microfoam of
0. 27. The injectable microfoam of
0. 28. The injectable microfoam of
0. 30. The injectable microfoam of
0. 31. The injectable microfoam of
0. 32. The injectable microfoam of
0. 34. The injectable microfoam of
0. 35. The injectable microfoam of
0. 36. The injectable microfoam of
|
|||||||||||||||||||||||||
This is a continuation of international application Serial No. PCT/ES94/00064, filed Jun. 21, 1994.
Schlerosis Sclerosis of varices is based on injecting liquid substances in them, which causing a localized inflammatory reaction propitiates the elimination of these abnormal veins.
Upon injecting a sclerosing agent, a mixture thereof with the blood contained in the vein is produced and diluted in an unknown proportion. The results are uncertain (due to overdose or underdose) and limited to short varicose segments. As the size of the varices to be injected decreases, the lesser this dilution is and the results that are obtained are more foreseeable. Nowadays, sclerosis is a technique chosen in cases of small and medium-sized varices. Surgery is used for those varices with a diameter equal to larger than 7 mm.
Sclerosis and surgery complement each other at this time, but sclerotherapy continues without being able to be applied to large varicose trunci.
In these large sized varices, upon injecting a sclerosing substance, the concentration thereof in the vein, its homogenous distribution in the blood and the time that it is going to be in contact with the inside walls of the treted treated vein are unknown.
In 1946 Orbach injected in small caliber varices some few cubic centimeters of air and verified displacement of the blood inside the vessel, which is occupied by the injected air. The sclerosing agent introduced afterwards is more effective than if it has been injected into the blood.
In thick varices, upon injecting air, the described phenomenon of displacement of the blood by the injected air does not take place, but rather this forms a bubble inside the vein that makes the process ineffective in these vessels.
This same author conceived, a few years late later, injection of foam obtained by agitating in a container containing sodium tetradecyl sulfate, an anionic sclerosing detergent with a high foaming capacity.
The process turns out to be rather useless due to the large-sized bubbles formed and dangerous due to the collateral effects of the atmospheric nitrogen, not very soluble in blood.
Both methods had very little practical repercussion as they were used only in small varices.
This invention refers to the preparation of a sclerosing microfoam.
In accordance with the present invention it has been discovered that injecting in a horizontal position a microfoam of pharmacologically inert sterile physiological serum, it is verified that the microfoam causes displacement of the blood contained in the vessel, even in more developed varices, due to the fact that the pressure of the blood contained in them horizontally is low.
The lifting of the injected member decreases even more the venous pressure, facilitating the exclusive filling of the vein with microfoam; this remaining in the vessel while the patient is not lifted from the examination table.
Upon replacing the prepared microfoam with the physiological serum by microfoam prepared with a sclerosing agent and injecting it in the vein, this displaces the blood that the vein contains and guarantees the contact of the sclerosis agent with the endothelium of the vein, at a known concentration and for a controllable amount of time, achieving sclerosis of the entire occupied segment.
The advantages of this process allow:
1. To know the concentration of the sclerosing agent in the vessel, as the microfoam displaces the blood and is not diluted in it like a liquid in it.
2. To guarantee the homogenous distribution of the product of sclerosis in the inside thereof.
3. To control the time in which it is kept in contact with the inside walls of the vein.
All of these factors are not known exactly nor are they controllable with the use of liquid sclerosing agents.
The elaboration of the present invention is carried out with the preparation of a microfoam with any sclerosing agent, such as: polydocanol polidocanol, sodium tetradecly tetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.
Once the sclerosing microfoam has been prepared by any one of the existing processes, two of which will be described hereinafter, it is introduced in any sterile vessel that can be used later to be injected in the vessels to be treated, and that permits the stability of the same, so that it can be removed by a syringe, or by any other instrument that allows injection thereof into the vessels to be treated.
The preparation of the sclerosing microfoam is done by mixing in a sterile, hermetic container and connected if desired to a bottle under oxygen pressure, mixture of oxygen and carbon dioxide or other physiological gasses gases; mechanical beating is carried out by means of a micromotor that makes an écouvillon submerged in the sclerosing solution to be foamed turn.
Beating between 8,000 and 15,000 rpm, for a time between 60 and 120 seconds, the microfoam is achieved.
This is introduced into any container that can be used for subsequent storage and later injection into the veins to be sclerosed.
In the event that the sclerosing agent does not have a foaming capacity Polysorbate 20, Polysorbate 80, Polygeline or any other substance with a foaming capacity accepted as inert for intravenous use is added to it.
The sclerosing agent is introduced into a hermetic, pressurized and sterile container and by stirring the solution the microfoam is achieved, with a outlet from the container for its subsequent use.
The invention can also embrace prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance. In one embodiment, the sclerosing substanc in the injectable microfoam is polidocanol. In another embodiment, it is sodium tetradecyl sulfate. In a further embodiment, it is a hypertonic glucostated or glucosaline solution. In still another embodiment, the sclerosing substance can be chromated glycerol. The sclerosing substance in another embodiment is ethanolamine oleate. Another embodiment could envisage sodium morrhuate as the sclerosing substance. Still another, envisages any iodated solution.
The present invention also uses the inventive microfoam in phlebology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in the treatment of esophageal varices. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in a proctology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in angiology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
Garrido, Juan Cabrera, Garcia-Olmedo, Juan Cabrera
| Patent | Priority | Assignee | Title |
| 10485767, | Feb 27 2015 | 10XBIO, LLC | Reduction of adipose tissue |
| 11065210, | Feb 27 2015 | 10XBIO, LLC | Reduction of adipose tissue |
| 7604185, | Nov 21 2002 | BTG International Ltd. | Generation of therapeutic microfoam |
| 7731986, | Nov 17 2003 | Boston Scientific Medical Device Limited | Therapeutic foam |
| 7763269, | Nov 17 2003 | Boston Scientific Medical Device Limited | Therapeutic foam |
| 7842282, | Nov 24 2000 | Boston Scientific Medical Device Limited | Generation of therapeutic microfoam |
| 7842283, | Nov 24 2000 | Boston Scientific Medical Device Limited | Generation of therapeutic microfoam |
| 8048439, | Nov 17 2003 | Boston Scientific Medical Device Limited | Therapeutic foam |
| 8091801, | May 26 1999 | BTG International Limited | Generation of therapeutic microfoam |
| 8323677, | Nov 17 2003 | BTG International Ltd. | Therapeutic foam |
| 8512680, | Aug 08 2001 | Biocompatibles UK Limited | Injectables in foam, new pharmaceutical applications |
| 8703827, | May 13 2005 | Boston Scientific Medical Device Limited | Therapeutic foam |
| 9351945, | Feb 27 2015 | 10XBIO, LLC | Reduction of adipose tissue |
| 9687455, | Aug 14 2014 | Sodium tetradecyl sulfate formulations for treatment of adipose tissue | |
| 9844520, | Feb 27 2015 | 10XBIO, LLC | Reduction of adipose tissue |
| Patent | Priority | Assignee | Title |
| 3698453, | |||
| 3970219, | Mar 03 1975 | Aerosol containers for foaming and delivering aerosols and process | |
| 4019657, | Mar 03 1975 | Aerosol containers for foaming and delivering aerosols | |
| 4040420, | Apr 22 1976 | Hughes Missile Systems Company | Packaging and dispensing kit |
| 4127131, | Jun 20 1977 | Johnson & Johnson | Hub assembly for use in the filtration of fluids and method of making the same |
| 4276885, | May 04 1979 | Schering, AG | Ultrasonic image enhancement |
| 4292972, | Jul 09 1980 | E R SQUIBB 6 SONS, INC | Lyophilized hydrocolloio foam |
| 4466442, | Oct 16 1981 | Schering Aktiengesellschaft | Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics |
| 4718433, | Jan 27 1983 | SLF LIMITED PARTNERSHIP | Contrast agents for ultrasonic imaging |
| 5064103, | May 23 1990 | RJS Industries, Inc. | Foam dispenser having a plurality of sieves |
| 5084011, | Jan 25 1990 | Method for oxygen therapy using hyperbarically oxygenated liquid | |
| 5141738, | Apr 15 1983 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
| 5542935, | Dec 22 1989 | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ASSIGNEE | Therapeutic delivery systems related applications |
| 5623085, | Sep 23 1994 | Rohm and Haas Company | Method for reducing microfoam in a spray-applied waterborne composition |
| 5656200, | Jan 23 1993 | Henkel Kommanditgesellschaft auf Aktien | Foaming emulsions |
| 5676962, | Jun 23 1993 | British Technology Group Limited | Injectable microfoam containing a sclerosing agent |
| 5902225, | Oct 11 1994 | S C JOHNSON & SON, INC | Post foamable multiple-sequential-foaming composition |
| 6561237, | Nov 28 2000 | Alltemp Products Company Limited | Apparatus and method for urging fluid into a pressurized system |
| CA1232837, | |||
| DE3048744, | |||
| DE3050812, | |||
| DE3417182, | |||
| DE69418286, | |||
| DE87046008, | |||
| EP54728, | |||
| EP77752, | |||
| EP123235, | |||
| EP131540, | |||
| EP217582, | |||
| EP324938, | |||
| EP359246, | |||
| EP656203, | |||
| EP997396, | |||
| EP324938, | |||
| ES2068151, | |||
| FR1547768, | |||
| FR2672038, | |||
| FR2775436, | |||
| WO24649, | |||
| WO66274, | |||
| WO72821, | |||
| WO9205806, | |||
| WO9500120, | |||
| WO9625194, | |||
| WO9943371, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 11 2003 | BTG International Limited | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Jul 15 2008 | ASPN: Payor Number Assigned. |
| Jul 15 2008 | RMPN: Payer Number De-assigned. |
| Date | Maintenance Schedule |
| Dec 13 2008 | 4 years fee payment window open |
| Jun 13 2009 | 6 months grace period start (w surcharge) |
| Dec 13 2009 | patent expiry (for year 4) |
| Dec 13 2011 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 13 2012 | 8 years fee payment window open |
| Jun 13 2013 | 6 months grace period start (w surcharge) |
| Dec 13 2013 | patent expiry (for year 8) |
| Dec 13 2015 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 13 2016 | 12 years fee payment window open |
| Jun 13 2017 | 6 months grace period start (w surcharge) |
| Dec 13 2017 | patent expiry (for year 12) |
| Dec 13 2019 | 2 years to revive unintentionally abandoned end. (for year 12) |